These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29709396)

  • 1. Rivaroxaban plus Percutaneous catheter-directed treatment for a patient with massive pulmonary embolism and colporrhagia.
    Wang W
    Am J Emerg Med; 2018 Aug; 36(8):1522.e5-1522.e7. PubMed ID: 29709396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge.
    Sharifi M; Bay C; Schwartz F; Skrocki L
    Clin Cardiol; 2014 Feb; 37(2):78-82. PubMed ID: 24122947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
    Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
    Barco S; Schmidtmann I; Ageno W; Bauersachs RM; Becattini C; Bernardi E; Beyer-Westendorf J; Bonacchini L; Brachmann J; Christ M; Czihal M; Duerschmied D; Empen K; Espinola-Klein C; Ficker JH; Fonseca C; Genth-Zotz S; Jiménez D; Harjola VP; Held M; Iogna Prat L; Lange TJ; Manolis A; Meyer A; Mustonen P; Rauch-Kroehnert U; Ruiz-Artacho P; Schellong S; Schwaiblmair M; Stahrenberg R; Westerweel PE; Wild PS; Konstantinides SV; Lankeit M;
    Eur Heart J; 2020 Jan; 41(4):509-518. PubMed ID: 31120118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
    Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
    Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-dose rivaroxaban in an 88-year-old female with pulmonary embolism: A case report.
    Zhou H; Wei Q; Wu H; Tang M; Yang S; Liu Y; Qin L
    Medicine (Baltimore); 2019 May; 98(20):e15705. PubMed ID: 31096518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
    Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
    J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
    Fermann GJ; Erkens PM; Prins MH; Wells PS; Pap ÁF; Lensing AW
    Acad Emerg Med; 2015 Mar; 22(3):299-307. PubMed ID: 25716463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
    Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
    Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia.
    Bethea BT; Elliot JW; Richardson JB; Ahmed MI
    Am J Health Syst Pharm; 2017 Aug; 74(15):1153-1157. PubMed ID: 28743779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
    Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
    Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.
    Groetzinger LM; Miller TJ; Rivosecchi RM; Smith RE; Gladwin MT; Rivera-Lebron BN
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):908-913. PubMed ID: 29455567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.